GLP-1药物可能会增加骨质疏松、痛风和骨质软化的风险,研究发现。 GLP-1 drugs may increase risks of osteoporosis, gout, and bone softening, study finds.

在美国矫形外科医生学会年会上提出的一项新的研究表明,根据对超过146 000名肥胖和2型糖尿病成人的分析,Ozempic和Wegovy等GLP-1类药物可能与略高的骨质疏松症、甲状腺病和骨瘤病风险有关。 A new study presented at the American Academy of Orthopaedic Surgeons’ annual meeting suggests GLP-1 drugs like Ozempic and Wegovy may be linked to a slightly higher risk of osteoporosis, gout, and osteomalacia, based on analysis of over 146,000 adults with obesity and Type 2 diabetes. 使用者患骨质疏松症的风险增加了30%,骨质疏松症的发病率增加了两倍,痛风发病率为7. 4%,而非使用者为6. 6%. Users had a 30% higher risk of osteoporosis and twice the rate of osteomalacia, with gout rates at 7.4% versus 6.6% in nonusers. 研究人员推测，快速减重和营养摄入减少可能导致骨质流失，而暂时的尿酸激增则可能增加痛风风险。 Researchers speculate rapid weight loss and reduced nutrient intake may contribute to bone loss, while temporary uric acid spikes could increase gout risk. 这项研究是观察性的,并不证明是因果关系,林业发展局以前曾指出老年人和妇女可能有骨折风险。 The study is observational and does not prove causation, and the FDA has previously noted possible fracture risks in older adults and women. 专家敦促监测骨骼健康,并与医生讨论风险,特别是高危病人的风险。 Experts urge monitoring bone health and discussing risks with doctors, especially for high-risk patients.